You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Clinical evidence

Looking to update your asthma or COPD guidelines? Here you’ll find the clinical evidence which supports the Ellipta range of medicines.

  • The evidence summary provides licensing information, clinical, financial and environmental data to support you to make an asthma formulary application and/or decide positioning within a local guideline.

    For more detailed clinical and graphical information on each of the clinical studies mentioned in the evidence summary, please consult the evidence dossier.

    Relvar Ellipta asthma evidence summary

    Download PDF

     

    Relvar Ellipta asthma evidence dossier

    Download PDF

     

  • Each of the evidence summaries provide licensing information, clinical, financial and environmental data to support you to make a COPD formulary application and/or decide positioning within a local guideline.

    For more detailed clinical and graphical information on each of the clinical studies mentioned in the evidence summary, please consult the relevant evidence dossier below.

    Trelegy Ellipta COPD evidence summary

    Download PDF

    Trelegy Ellipta COPD evidence dossier

    Download PDF

    Anoro Ellipta COPD evidence summary

    Download PDF

    Anoro Ellipta COPD evidence dossier

    Download PDF

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Anoro, Ellipta, Relvar and Trelegy are registered trademarks of the GlaxoSmithKline group of companies